Policy Watch: 20 Regulatory Updates — March 12, 2026
This Policy Watch highlights cannabis regulatory updates March 2026, focusing on federal scheduling and Medicare policy changes. These updates impact cannabis clinicians' prescribing authority and patient access. Stay current with the latest cannabis…
Clinical Implications of Marijuana Rescheduling
Marijuana rescheduling clinical implications are significant for research and medical practice. Rescheduling to Schedule III reduces barriers for clinical studies and may improve patient access. Clinicians should stay informed about evolving regulations…
Federal Order Does Not Legalize Recreational Marijuana, Senator Clarifies
The cannabis rescheduling executive order shifts marijuana from Schedule I to Schedule III, easing research restrictions but not legalizing recreational use. This federal policy clarification highlights that full legalization requires Congressional…
Cannabis Use Disorder Clinical Trial Pipeline Gains Momentum
The cannabis use disorder treatment pipeline is gaining momentum with new clinical trials advancing targeted therapies. Research focuses on developing pharmacotherapies for cannabis addiction. This progress addresses the urgent need for evidence-based…
Cannabis Rescheduling Update: Advocates Eye AG Bondi Hearing for Status Report
Cannabis rescheduling update highlights potential easing of research restrictions and tax burdens. Advocates closely watch Attorney General Pam Bondi's hearing for status. This update clarifies that only Congress can legalize recreational marijuana.